Earlymarket has recently welcomed its latest investment, Pear Bio, into its portfolio - a new addition within their Personalised Healthcare investment theme.
Driving this innovative venture is nanotechnologist and entrepreneur, Duleek Ranatunga, who aims to disrupt the landscape of cancer therapeutics by making personalised treatments for cancer patients a tangible reality.
Following a highly successful Series A fundraising round, Pear Bio secured $14m in investment, led by Octopus Ventures, and a wealth of experienced investors, including Hoxton Ventures, Crista Galli Ventures, SOSV, Fly Ventures, and Compound Ventures.
Pear Bio's organ-on-a-chip technology and sophisticated computer vision software enables doctors to tailor cancer therapies to individuals. Recognising the uniqueness of cancer and the variances in patients' responses to treatment, Pear Bio empowers doctors with a robust predictive tool for assessing an individual's response to treatments, ultimately leading to enhanced recovery rates for patients. This is particularly important for complex cancer cases that have historically been difficult to treat.
The potential impact of Pear Bio on the lives of millions is vast. By improving recovery rates, especially for cancers that have been underserved, this company is charting a new course in the fight against cancer.
What sets Pear Bio apart is its sophisticated and proprietary computer vision technology, which not only predicts drug responses within patient tumours but also assesses patients immune responses. This ground-breaking capability distinguishes Pear Bio from other microtumour technology firms and has garnered significant interest from pharmaceutical companies seeking to advance their R&D studies on efficacy of new cancer therapies. Further details of Pear Bio’s unique offering is shared within a recent article by Sifted.
As part of their strategic roadmap, Pear Bio is gearing up for an expansion into the United States to sell tests directly to patients. This will require a full CLIA lab to be set up, of which has already been identified and begun formation.
Pear Bio’s journey represents a bold step towards a future where cancer can be treated with greater precision and efficacy, tailored for the individual - a journey that Earlymarket is undeniably excited to be a part of.
Driving this innovative venture is nanotechnologist and entrepreneur, Duleek Ranatunga, who aims to disrupt the landscape of cancer therapeutics by making personalised treatments for cancer patients a tangible reality.
Following a highly successful Series A fundraising round, Pear Bio secured $14m in investment, led by Octopus Ventures, and a wealth of experienced investors, including Hoxton Ventures, Crista Galli Ventures, SOSV, Fly Ventures, and Compound Ventures.
Pear Bio's organ-on-a-chip technology and sophisticated computer vision software enables doctors to tailor cancer therapies to individuals. Recognising the uniqueness of cancer and the variances in patients' responses to treatment, Pear Bio empowers doctors with a robust predictive tool for assessing an individual's response to treatments, ultimately leading to enhanced recovery rates for patients. This is particularly important for complex cancer cases that have historically been difficult to treat.
The potential impact of Pear Bio on the lives of millions is vast. By improving recovery rates, especially for cancers that have been underserved, this company is charting a new course in the fight against cancer.
What sets Pear Bio apart is its sophisticated and proprietary computer vision technology, which not only predicts drug responses within patient tumours but also assesses patients immune responses. This ground-breaking capability distinguishes Pear Bio from other microtumour technology firms and has garnered significant interest from pharmaceutical companies seeking to advance their R&D studies on efficacy of new cancer therapies. Further details of Pear Bio’s unique offering is shared within a recent article by Sifted.
As part of their strategic roadmap, Pear Bio is gearing up for an expansion into the United States to sell tests directly to patients. This will require a full CLIA lab to be set up, of which has already been identified and begun formation.
Pear Bio’s journey represents a bold step towards a future where cancer can be treated with greater precision and efficacy, tailored for the individual - a journey that Earlymarket is undeniably excited to be a part of.